Literature DB >> 11790287

Genetics of the mineralocorticoid system in primary hypertension.

Paolo Ferrari1.   

Abstract

Abnormalities in steroid biosynthesis have been known for years to cause hypertension in some cases of congenital adrenal hyperplasia. In these patients hypertension usually accompanies a characteristic phenotype with abnormal sexual differentiation. Recently, the molecular basis of four forms of severe hypertension transmitted on an autosomal basis but without additional phenotypic features has been elucidated. All these conditions are characterized primarily by low plasma renin, normal or low serum potassium, and salt-sensitive hypertension, indicating an increased mineralocorticoid effect. These four disorders, the glucocorticoid remediable aldosteronism, the syndrome of apparent mineralocorticoid excess, the activating mutation of the mineralocorticoid receptor, and the Liddle syndrome are a consequence of either abnormal biosynthesis, metabolism, or action of steroid hormones, and are ultimately characterized by an overactivation of the epithelial sodium channel in distal renal tubules. Hyperactivity of this channel results in increased sodium reabsorption and volume expansion leading to an increase in blood pressure as well as potassium loss. With the advent of molecular biology in clinical practice, it has become evident that some genetic defect may present with a more discrete phenotype, with only moderate hypertension with or without hypokalemia as the sole feature. A search for genetic disorders of the mineralocorticoid axis should be an integral part of the diagnostic work-up, particularly in young adults with hypertension.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11790287     DOI: 10.1007/s11906-002-0048-8

Source DB:  PubMed          Journal:  Curr Hypertens Rep        ISSN: 1522-6417            Impact factor:   5.369


  38 in total

1.  Angiotensin II and potassium regulate human CYP11B2 transcription through common cis-elements.

Authors:  C D Clyne; Y Zhang; L Slutsker; J M Mathis; P C White; W E Rainey
Journal:  Mol Endocrinol       Date:  1997-05

Review 2.  The steroid receptor superfamily: mechanisms of diversity.

Authors:  P J Fuller
Journal:  FASEB J       Date:  1991-12       Impact factor: 5.191

3.  Biochemical evidence of aldosterone overproduction and abnormal regulation in normotensive individuals with familial hyperaldosteronism type I.

Authors:  M Stowasser; P R Huggard; T R Rossetti; A W Bachmann; R D Gordon
Journal:  J Clin Endocrinol Metab       Date:  1999-11       Impact factor: 5.958

4.  Several homozygous mutations in the gene for 11 beta-hydroxysteroid dehydrogenase type 2 in patients with apparent mineralocorticoid excess.

Authors:  R C Wilson; M D Harbison; Z S Krozowski; J W Funder; C H Shackleton; H M Hanauske-Abel; J Q Wei; J Hertecant; A Moran; R E Neiberger
Journal:  J Clin Endocrinol Metab       Date:  1995-11       Impact factor: 5.958

Review 5.  A genetic defect resulting in mild low-renin hypertension.

Authors:  R C Wilson; S Dave-Sharma; J Q Wei; V R Obeyesekere; K Li; P Ferrari; Z S Krozowski; C H Shackleton; L Bradlow; T Wiens; M I New
Journal:  Proc Natl Acad Sci U S A       Date:  1998-08-18       Impact factor: 11.205

6.  The human gene for 11 beta-hydroxysteroid dehydrogenase. Structure, tissue distribution, and chromosomal localization.

Authors:  G M Tannin; A K Agarwal; C Monder; M I New; P C White
Journal:  J Biol Chem       Date:  1991-09-05       Impact factor: 5.157

Review 7.  Aldosterone regulation of gene transcription leading to control of ion transport.

Authors:  J D Horisberger; B C Rossier
Journal:  Hypertension       Date:  1992-03       Impact factor: 10.190

8.  A chimaeric 11 beta-hydroxylase/aldosterone synthase gene causes glucocorticoid-remediable aldosteronism and human hypertension.

Authors:  R P Lifton; R G Dluhy; M Powers; G M Rich; S Cook; S Ulick; J M Lalouel
Journal:  Nature       Date:  1992-01-16       Impact factor: 49.962

9.  Point mutations abolish 11 beta-hydroxysteroid dehydrogenase type II activity in three families with the congenital syndrome of apparent mineralocorticoid excess.

Authors:  P Ferrari; V R Obeyesekere; K Li; R C Wilson; M I New; J W Funder; Z S Krozowski
Journal:  Mol Cell Endocrinol       Date:  1996-05-17       Impact factor: 4.102

10.  Human hypertension caused by mutations in the kidney isozyme of 11 beta-hydroxysteroid dehydrogenase.

Authors:  T Mune; F M Rogerson; H Nikkilä; A K Agarwal; P C White
Journal:  Nat Genet       Date:  1995-08       Impact factor: 38.330

View more
  4 in total

1.  The distinction between Liddle syndrome and apparent mineralocorticoid excess.

Authors:  Mario G Bianchetti; Giacomo D Simonetti; Paolo Ferrari
Journal:  Pediatr Nephrol       Date:  2003-01-24       Impact factor: 3.714

Review 2.  The dopamine paradox in lung and kidney epithelia: sharing the same target but operating different signaling networks.

Authors:  Alejandro M Bertorello; Jacob I Sznajder
Journal:  Am J Respir Cell Mol Biol       Date:  2005-11       Impact factor: 6.914

Review 3.  Aldosterone receptor antagonists: biology and novel therapeutical applications.

Authors:  P Magni; M Motta
Journal:  J Endocrinol Invest       Date:  2003-08       Impact factor: 4.256

4.  Association Between NR3C1 Gene Polymorphisms and Toxicity Induced by Glucocorticoids Therapy in Saudi Children with Acute Lymphoblastic Leukemia

Authors:  Refaat El-Fayoumi; Magda Hagras; Adel Abozenadaha; Waleed Bawazir; Thoraia Shinawi
Journal:  Asian Pac J Cancer Prev       Date:  2018-05-26
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.